Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Docking, Synthesis and Evaluation of 4-hydroxy-1-phenyl-2(1H)-quinolone Derivatives as Anticancer Agents

Author(s): Chaitali Prabhu Tendulkar, Prachita Gauns Dessai*, Shivlingrao Mamle Desai and Amrita Kadam

Volume 21, Issue 2, 2024

Published on: 11 September, 2023

Article ID: e190723218893 Pages: 11

DOI: 10.2174/1570163820666230719110932

Price: $65

Abstract

Background: The estimated number of cancer cases in India for the year 2022 was found to be 14,61,427. The development of chemotherapeutic agents has reduced the mortality rate, however, they have high toxicity which is a disadvantage. Many researchers have found out that quinolin-2- one possesses anticancer activity, with this background we thought of synthesizing the quinolin-2-one derivatives.

Objective: This study aimed to carry out docking, synthesis, characterization, and evaluation of 2-(2- (4-Hydroxy-2-oxoquinolin-1(2H)-yl)phenyl/ substituted phenyl)-3-(phenylamino) thiazolidon-4-one derivatives (IVa-g) as an anticancer agent.

Method: Diphenylamine and malonic acid treated with phosphoryl chloride gave compound I, which on formylation afforded compound II, which on reaction with various substituted aromatic phenylhydrazine derivatives gave compounds IIIa-g, which on further reaction with thioglycolic acid and anhydrous zinc chloride yielded the compounds IVa-g.

Result: Among all the synthesized novel derivatives, compounds IV a-d showed 50% lysis in the IC50 range of 25-50μg for the A549 cell line, and compounds IVa, and IVb showed 50% lysis in the IC50 range of 25-50μg for the MDA-MB cell line. The compound, 3-((4-fluorophenyl)amino)-2-(2-(4- hydroxy-2-oxoquinolin-1(2H)-yl)phenyl)thiazolidin-4-one (IVg) was found to be the most active against both the cell line, A549 and MDA-MB with IC50 value of 0.0298μmol and 0.0338μmol respectively. The docking results revealed that the synthesized compounds exhibited well-conserved hydrogen bonding with one or more amino acid residues in the active pocket of EGFR tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib (PDB ID:1M17). Compound IVg showed the highest MolDock score of -137.813 compared to the standard drug Imatinib having a MolDock score of -119.354.

Conclusion: Compound IVg showed the highest MolDock score and was also found to be most potent against both the cell line, A549, and MDA-MB.

Graphical Abstract

[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[http://dx.doi.org/10.3322/caac.201072] [PMID: 21296855]
[2]
Priolkar RNS, Shingade S, Palkar M, Desai SM. Design, synthesis, and characterization of novel linomide analogues and their evaluation for anticancer activity. Curr Drug Discov Technol 2020; 17(2): 203-12.
[http://dx.doi.org/10.2174/15701638156661810081510373] [PMID: 30306874]
[3]
Dessai PG, Dessai SP, Dabholkar R, et al. Design, synthesis, graph theoretical analysis and molecular modelling studies of novel substituted quinoline analogues as promising anti-breast cancer agents. Mol Divers 2022; 27(4): 1567-86.
[http://dx.doi.org/10.1007/s11030-022-10512-7] [PMID: 35976550]
[4]
Shaikh K, Krishnan S, Thanki RM. Artifcial intelligence in breast cancer early detection and diagnosis. Springer 2021.
[5]
Alfonse M, Aref MM, Salem A-BM. An ontology-based system for cancer diseases knowledge management. Int J Inf Eng Electron Bus 2014; 6(6): 55-63.
[6]
Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res 2022; 156(4 & 5): 598-607.
[7]
Kleihues P, Sobin LH. World Health Organization classifcation of tumors. Cancer 2000; 88(12): 2887.
[8]
Cancer. Available From: https://www.who.int/news-room/factsheets/detail/cancer
[9]
Jain S, Chandra V, Jain PK, Pathak K, Pathak D, Vaidya A. Comprehensive review on current developments of quinoline-based anticancer agents. Arab J Chem 2019; 12(8): 4920-46.
[10]
Chen IL, Chen JJ, Lin YC, Peng CT, Juang SH, Wang TC. Synthesis and antiproliferative activities of N-(napthalen-2-yl) acetamide and N-(substituted phenyl)acetamide bearing quinolin-2(1H)-one and 3,4-dihydroquinolin-2(1H)-one derivatives. Eur J Med Chem 2013; 59: 227-34.
[PMID: 23229058]
[11]
Abonia R, Insuasty D, Castillo J, et al. Synthesis of novel quinoline-2-one based chalcones of potential anti-tumor activity. Eur J Med Chem 2012; 57: 29-40.
[PMID: 23043766]
[12]
Bajaj P, Mamle Desai S, Dighe P, Naik S, Biradar B. Synthesis of 4-hydroxy-3-(1-hydroxy-2-(substitutedamino)ethyl)-1- phenyl/methylquinolin-2(1H)-one as anticancer agents. Asian J Pharm Clin Res 2017; 10: 225-8.
[13]
Kharb R, Kaur H. Therapeutic significance of quinoline derivatives as antimicrobial agents. IRJP 2013; 4: 63-9.
[14]
Liu HB, Tang H, Yang D, Deng Q, Yuan LJ, Ji QG. Synthesis and biological evaluation of novel N-acyl substituted quinolin-2(1H)-one derivatives as potential antimicrobial agents. Bioorg Med Chem Lett 2012; 22(18): 5845-8.
[PMID: 22902657]
[15]
Ferretti MD, Neto AT, Morel AF, Kaufman TS, Larghi EL. Synthesis of symmetrically substituted 3,3-dibenzyl-4-hydroxy-3,4-dihydro-1H-quinolin-2-ones, as novel quinoline derivatives with antibacterial activity. Eur J Med Chem 2014; 81: 253-66.
[PMID: 24852274]
[16]
Rajadhyax A, Mamle Desai S, Naik S, Tari P. Synthesis of 4-methoxy-1-phenyl/methyl-3-[5-(phenyl/substitutedphenyl)-4,5- dihydro-(1H)-pyrazol-3-yl]quinolin-2(1H)-one derivatives as antibacterial agents. Indian J Heterocycl Chem 2015; 25: 173-6.
[17]
Curreli F, Zhang H, Zhang X, et al. Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid. Bioorg Med Chem 2011; 19(1): 77-90.
[PMID: 21168336]
[18]
Cheng P, Gu Q, Liu W, et al. Synthesis of quinolin-2-one alkaloid derivatives and their inhibitory activities against HIV-1 reverse transcriptase. Molecules 2011; 16(9): 7649-61.
[PMID: 21900867]
[19]
Sala M, Chimento A, Saturnino C, et al. Synthesis and cytotoxic activity evaluation of 2,3-thiazolidin-4-one derivatives on human breast cancer cell lines. Bioorg Med Chem Lett 2013; 23(17): 4990-5.
[PMID: 23860590]
[20]
Reis M, Mamle Desai S, Naik S, Fernandes J, Tari P. Synthesis and evaluation of 2-(4-methoxy-2-oxo-1-phenyl/methyl-1,2- dihydroquinolin-3-yl)-2-methyl-3-(phenyl/substituted phenylamino)thiazolidin-4-one as antibacterial and anticancer agents. Indian J Chem Sect B 2016; 55: 1254-8.
[21]
Revelant G, Huber-Villaume S, Dunand S, Kirsch G, Schohn H, Hesse S. Synthesis and biological evaluation of novel 2-heteroarylimino-1,3-thiazolidin-4-ones as potential anti-tumor agents. Eur J Med Chem 2015; 94: 102-12.
[PMID: 25757093]
[22]
Hu J, Wang Y, Wei X, et al. Synthesis and biological evaluation of novel thiazolidinone derivatives as potential anti-inflammatory agents. Eur J Med Chem 2013; 64: 292-301.
[PMID: 23644212]
[23]
Suthar SK, Jaiswal V, Lohan S, et al. Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening. Eur J Med Chem 2013; 63: 589-602.
[PMID: 23548704]
[24]
Murugesan V, Makwana N, Suryawanshi R, et al. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2014; 22(12): 3159-70.
[PMID: 24794742]
[25]
Küçükgüzel I, Satılmış G, Gurukumar KR, et al. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase. Eur J Med Chem 2013; 69: 931-41.
[PMID: 24161679]
[26]
Patel NB, Patel JC, Patel VN. Synthesis and antimicrobial activity of quinazolin-4(3H)-ones incorporating sulfonamido-4-thiazolidinone. Chin J Chem 2010; 28: 1989-97.
[27]
Desai NC, Dodiya AM, Makwana AH. Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo thiazolidine derivatives. Med Chem Res 2012; 21: 2320-8.
[28]
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315(3): 971-9.
[PMID: 16002463]
[29]
Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: A selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38 (Suppl. 5): S19-27.
[PMID: 12528769]
[30]
Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: An update of recent developments. Ann Surg Oncol 2007; 14(2): 942-53.
[PMID: 17103252]
[31]
Kadam AM. MamleDesai SN, Prabhutendulkar C. Synthesis and characterization of quinolin-2-one derivatives as possible cytotoxic agents. European Journal of Biomedical and Pharmaceutical Sciences 2018; 5(1): 900-5.
[32]
Palkar MB, Singhai AS, Ronad PM, et al. Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents. Bioorg Med Chem 2014; 22(10): 2855-66.
[PMID: 24751552]
[33]
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.
[PMID: 6606682]
[34]
Rashad FM, Abd El-Nasser NH, Dawoud IF, Motawe FH. Isolation and characterization of antibiotic/antitumor producing streptomyces. Res J Pharm Biol Chem Sci 2015; 6(2): 1919.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy